Bohui Innovation BH100 Fluorescent Immunochromatographic Analyzer
| Brand | Bohui Innovation |
|---|---|
| Origin | Beijing, China |
| Model | BH100 |
| Detection Principle | Fluorescent Immunochromatography (Dual-Antibody Sandwich) |
| Assay Time | <30 s per test |
| Linear Range | 0–500 ng/mL (fluorescein standard, r ≥ 0.990) |
| Background Noise | <50 RFU (10× blank card avg.) |
| Accuracy | ±5% of labeled value (fluorescein calibrator) |
| Precision | CV ≤10% at 100 ng/mL |
| Stability | <5% fluorescence drift within 20 min |
| Power Supply | 220 V, 50 Hz |
| Operating Environment | 10–30 °C, ≤70% RH, altitude <2000 m |
| Dimensions | 400 × 436 × 200 mm |
Overview
The Bohui Innovation BH100 Fluorescent Immunochromatographic Analyzer is a dedicated benchtop instrument engineered for rapid, quantitative detection of viral antigens in clinical specimens using time-resolved fluorescent immunochromatography. It operates on the dual-antibody sandwich principle: sample antigens—specifically rotavirus and enteric adenovirus—are captured by immobilized monoclonal antibodies on nitrocellulose membrane test lines, while simultaneously bound by fluorescent-labeled detection antibodies. The instrument quantifies emitted fluorescence intensity at the test and control lines using a calibrated photomultiplier tube (PMT) or solid-state detector, converting raw signal into concentration-equivalent values via preloaded calibration curves. Designed for integration into high-throughput clinical microbiology and point-of-care testing (POCT) workflows, the BH100 delivers objective, operator-independent results with minimal hands-on time—eliminating subjective visual interpretation inherent in conventional lateral flow assays.
Key Features
- Quantitative fluorescence readout with sub-50 RFU background noise floor, enabling high-sensitivity antigen detection below clinically relevant thresholds.
- Single-test cycle completed in under 30 seconds—optimized for batch processing of multiple samples without manual intervention between runs.
- Integrated thermal and optical stabilization ensures <5% fluorescence signal drift over 20 minutes, supporting extended unattended operation during peak laboratory shifts.
- Predefined linear dynamic range of 0–500 ng/mL (validated against fluorescein reference standards, r ≥ 0.990), facilitating reliable semi-quantitative to quantitative reporting.
- Rigorous metrological performance: accuracy within ±5% of nominal calibrator values; precision demonstrated by ≤10% coefficient of variation at 100 ng/mL.
- Compact footprint (400 × 436 × 200 mm) and low electromagnetic emissions permit deployment in shared diagnostic workspaces compliant with IEC 61326-1 requirements.
Sample Compatibility & Compliance
The BH100 is validated exclusively for use with Bohui Innovation’s CE-marked, in vitro diagnostic (IVD) lateral flow test strips—including the Rotavirus/Enteric Adenovirus Combo Kit—for human stool specimen analysis. It complies with ISO 13485:2016 quality management system requirements for medical device manufacturers. While not FDA 510(k)-cleared for U.S. distribution, its analytical performance aligns with CLSI EP15-A3 guidelines for precision and EP09-A3 for method comparison studies. Instrument firmware supports audit-trail logging per GLP/GMP principles, including user ID, timestamp, test ID, raw fluorescence values, and pass/fail status—essential for laboratories undergoing CAP or ISO 15189 accreditation.
Software & Data Management
The BH100 interfaces bidirectionally with Laboratory Information Systems (LIS) and Hospital Information Systems (HIS) via ASTM E1384-compliant HL7 v2.5 messaging. All measurement data—including raw RFU values, calculated concentrations, QC flag status, and instrument operational logs—are stored locally in encrypted SQLite databases with configurable retention policies. Software provides built-in QC charting (Levey-Jennings plots), automated calibration verification alerts, and export capabilities in CSV and PDF formats suitable for regulatory submissions. No cloud dependency: all data remains on-premise unless explicitly routed through hospital-approved network gateways.
Applications
Primary clinical utility includes rapid triage of acute pediatric gastroenteritis in emergency departments, outpatient clinics, and reference laboratories. The system supports differential diagnosis of rotavirus versus enteric adenovirus infection—both major causes of severe dehydrating diarrhea in children under five. Its quantitative output enables longitudinal monitoring of antigen load trends during treatment response assessment. Beyond routine diagnostics, the platform’s open assay architecture permits validation of additional fluorescently labeled lateral flow tests targeting norovirus, astrovirus, or bacterial toxins (e.g., Clostridioides difficile toxin A/B), subject to local regulatory clearance.
FAQ
What sample types are compatible with the BH100?
Stool specimens processed using Bohui Innovation’s proprietary extraction buffer and applied to designated combo test strips—no serum, plasma, or urine validation provided.
Does the BH100 require daily calibration?
No routine daily calibration is required; however, calibration verification using included fluorescein standards must be performed before first use each day and after any maintenance event.
Can the BH100 operate in ambient lighting conditions?
Yes—the optical enclosure is light-tight and internally shielded; no darkroom or ambient light restrictions apply.
Is the software compatible with Windows 10/11 64-bit operating systems?
Yes—client software is certified for Windows 10 Pro and Windows 11 Enterprise editions with .NET Framework 4.8 or later.
What is the minimum detectable fluorescence intensity?
Instrument detection limit is defined as mean blank + 3SD, empirically verified at <50 RFU across ten consecutive blank strip measurements.
